# Jet vaccination with pBI-11 DNA to treat HPV16/18+ ASC-US/LSIL

> **NIH NIH P50** · JOHNS HOPKINS UNIVERSITY · 2024 · $283,663

## Abstract

Project Summary/Abstract
HPV16 remains the most prevalent oncogenic genotype, responsible for over half of all cervical cancer cases
worldwide, and HPV18 contributes another 20%. The licensed preventive HPV vaccines are not effective to
treat HPV16/18 infection or disease identified in population-based cervical screening. Nearly half of all
persistent HPV16 infections and a quarter of HPV18 progress to high grade cervical intraepithelial neoplasia
(CIN2/3), the precursor of cervical cancer, and the risk of HPV persistence increases with age. Currently, there
are no treatment options available for persistent HPV16/18 infections that have not yet progressed to high
grade cervical intraepithelial neoplasia (<CIN2), other than continued screening until progression, with
subsequent surgery for CIN2/3. Patients with persistent cervical HPV16/18 infections have significant potential
for transmission and/or the development of disease at other sites, and suffer considerable psychosocial stress
associated with having a sexually-transmitted infection that can cause cancer. Therefore, there is a clear
unmet medical need for a therapeutic medical intervention to safely eliminate persistent HPV16/18 infections
before oncogenic progression. Patients with a persistent HPV16/18 infection are likely to be highly motivated to
receive such a therapy and avoid progression requiring an excisional procedure that is associated with
significant rates of recurrence and side effects including infection, cervical incompetence and premature birth.
The goal of this proposal is to develop a treatment regimen that safely and effectively elicits immune clearance
of persistent cervical HPV16/18 infections, thereby intercepting progression to cervical cancer precursor
lesions and cervical cancer. We developed a DNA vaccine, pBI-11, encoding HPV16/18 E6 and E7 proteins
that are linked to the danger-associated molecular pattern (DAMP) heat shock protein 70 (HSP70) because it
dramatically enhances HPV antigen-specific CD8+ T cell immunity and antitumor potency in mice. However,
DNA vaccines alone have shown limited potency in patients because of inefficient delivery. Needle-free
delivery of a naked DNA vaccine (ZyCov-D) with a jet device was shown to be safe and effective for prevention
of SARS-CoV2 and received licensure in India, demonstrating the utility of these devices in patients for potent
delivery of a DNA vaccine. The Specific Aims of our randomized, double-blind phase II study are: (1) To
assess the safety, tolerability and feasibility of repeat intradermal or intramuscular vaccination with
pBI-11 DNA via a needle-free jet device in women with HPV16 and/or HPV18+ <CIN2 cervical disease;
(2) To determine the immunogenicity of intradermal or intramuscular jet administration of pBI-11 DNA
to women with HPV16/18+ <CIN2 cervical disease; (3) To examine virologic, cytologic, and pathologic
changes at the cervix upon repeat intradermal or intramuscular needle-free jet administrati...

## Key facts

- **NIH application ID:** 10935440
- **Project number:** 2P50CA098252-21
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** Chien-Fu Hung
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $283,663
- **Award type:** 2
- **Project period:** 2003-09-30 → 2029-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10935440

## Citation

> US National Institutes of Health, RePORTER application 10935440, Jet vaccination with pBI-11 DNA to treat HPV16/18+ ASC-US/LSIL (2P50CA098252-21). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10935440. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*